tbuckley/cabot-search huggingface dataset:
A Nonparametric Method for Estimating Interaction Effect of Age and Period on Mortality
Authors: Megu Ohtaki, Dong-Kyu Kim, Masaki Munaka
Journal: Environmental Health Perspectives (1990)

In this paper we introduce a new model and develop an estimation strategy to analyze mortality data. The model we dealt with has the specific structure E[log qij] = mu + alpha i + beta j + rho ij subject to the linear restrictions sigma i alpha i/sigma 2i = sigma j beta j = sigma i pij/sigma 2i = sigma j rho ij = 0 for any i and j; here, qij denotes the mortality for the jth period category and ith age category, mu denotes the overall mean, alpha i denotes the ith age effect in antichronological order, beta j the jth period effect, rho ij the general interaction effect; and sigma 2i is the common error variance of log qij for the ith age group. We propose a combined technique of ANOVA and nonparametric smoothing for estimating these parameters. The methods described are illustrated by mortality data on rectum cancer in Japanese males and females between 1950-1986.
SURGEON'S MASK FOR THOSE WHO WEAR GLASSES
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Princely Gift.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The hallucinatory effect of pentazocine (Talwin)
Authors: N. DeNosaquo
Journal: JAMA (1969)

The Food and Drug Administration approved the use of pentazocine (Talwin) in July 1967. The first report of an adverse reaction induced by this drug was received by the American Medical Association Registry on Adverse Reactions in August 1967. Since then, 20 reports have been received. Seven (35%) of these reports cited the hallucinatory effect associated with the use of pentazocine, while the others reported symptoms that included drowsiness, dizziness, inability to think, vertigo, vomiting, euphoria, incoordination exhaustion, extrapyramidal effects, confusion, rhinorrhea, hives, nausea, muscular tremor, and tightness of the chest. In the labeling of pentazocine the manufacturer has pointed out that the drug also has been associated with these adverse effects: nausea, vertigo, dizziness or lightheadedness, vomiting, euphoria, hallucinations, disorientation, weakness, muscle tremor, insomnia, and allergic reactions including edema of the face. This communication concerns the seven individuals who experienced the hallucinatory effect associated with the use of pentazocine.
The molecular basis of proteinuria
Authors: R. P. Misra
Journal: JAMA (1979)

HIPPOCRATES observed more than 2,000 years ago that "bubbles on the surface of the urine are a sign of diseases of the kidney." One might speak today of protein molecules altering surface tension and thereby producing foam, but the bedside sign described so long ago remains valid. The stately pace of medicine saw two millenia go by uneventfully until Dekkers demonstrated proteinuria in 1695 by boiling acidified urine and producing a precipitate. A century later, in 1798 Cruickshank showed that "the coagulable part of the serum is detected in morbid states of the urine."<sup>1</sup>Bright,<sup>2</sup>busy laying the foundation of modern nephrology from 1827 to 1840, noted that patients with massive proteinuria could experience hypoproteinemia. Nineteenth-century workers further developed the concept that the kidney acted as a semipermeable membrane that, in health, prevented the loss of plasma protein in the urine. It was assumed that an injured kidney
The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective
Authors: R. M. Califf
Journal: JAMA (1989)

To elucidate the factors associated with improved survival following coronary artery bypass surgery, we studied 5809 patients receiving medical or surgical therapy for coronary artery disease. Three factors were associated with a significant surgical survival benefit: more severe coronary disease, a worse prognosis with medical therapy, and a more recent operative date. Patients with more extensive coronary obstruction had the greatest improvement in survival. Patients with a poor prognosis because of factors such as older age, severe angina, or left ventricular dysfunction had a reduction in risk that was proportionate to their overall risk on medical therapy. Survival with surgery progressively improved over the study period and by 1984 surgery was significantly better than medical therapy for most patient subgroups. Thus, contemporary coronary revascularization is associated with improved longevity in many patients with ischemic heart disease, especially in those with adverse prognostic indicators. (<i>JAMA</i>. 1989;261:2077-2086)
National Institutes of Health Consensus Development Conference on Drugs and Insomnia
Journal: JNCI Journal of the National Cancer Institute (1983)

National Institutes of Health Consensus Development Conference on Drugs and Insomnia Get access JNCI: Journal of the National Cancer Institute, Volume 71, Issue 3, September 1983, Page 649, https://doi.org/10.1093/jnci/71.3.649-c Published: 01 September 1983
Genetic variant PNPLA3 I148M accelerates fat accumulation in livers of mice with ASH/NASH via damping of PPAR alpha and PPAR gamma signalling pathways
Authors: Eleonora Patsenker, Veera Raghavan Thangapandi, Jane Beil-Wagner, Thorsten Buch, Johannes vom Berg, Jochen Hampe, Felix Stickel
Journal: Journal of Hepatology (2020)
<i>Clinique des Maladies du Systéme Nerveux.</i>M. le Professeur CHARCOTS Leçons du Professeur, Mémoire, Notes et Observations. Parues pendant les Années. 1889-90 et 1890-91, et Publiéés sous la Direction de Georges Guinon. Chef de Clinique, &amp;c. Tome I. Paris, 1892
Authors: H. M. B.
Journal: American Journal of Psychiatry (1892)
THE ENGLISH HIPPOCRATES
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P55 Benefits of tiotropium/olodaterol on symptoms and health-related quality of life in patients with moderate to severe copd with chronic bronchitis and/or emphysema
Journal: Thorax (2016)

AbstractGT Ferguson, during the conduct of the study, reports grants, personal fees and non-financial support from Boehringer Ingelheim and, outside the submitted work, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, AstraZeneca, Pearl Therapeutics and Sunovion, and grants from Forest.R Abrahams reports grants and personal fees from Boehringer Ingelheim during the conduct of the study and, outside of this work, grants and personal fees from GlaxoSmithKline and grants from AstraZeneca and Pearl Therapeutics.L Bjermer reports no conflicts of interest.L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.D Singh reports other financial activities from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, and personal fees from Genentech and SkyePharma.
Psychiatry, Court
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PRESIDENT'S CALL FOR VOLUNTEERS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 &amp; 2)
Authors: Mette Deleuran, Emma Guttman-Yassky, Kulli Kingo, Neil M.H. Graham, Gianluca Pirozzi, Bolanle Akinlade, Laurent Eckert, Abhijit Gadkari, Marius Ardeleanu
Journal: Journal of Allergy and Clinical Immunology (2018)
Both the environment and genes are important for concentrations of cadmium and lead in blood.
Authors: L Björkman, M Vahter, N L Pedersen
Journal: Environmental Health Perspectives (2000)

Concentrations of cadmium and lead in blood (BCd and BPb, respectively) are traditionally used as biomarkers of environmental exposure. We estimated the influence of genetic factors on these markers in a cohort of 61 monozygotic and 103 dizygotic twin pairs (mean age = 68 years, range = 49-86). BCd and BPb were determined by graphite furnace atomic absorption spectrophotometry. Variations in both BCd and BPb were influenced by not only environmental but also genetic factors. Interestingly, the genetic influence was considerably greater for nonsmoking women (h(2) = 65% for BCd and 58% for BPb) than for nonsmoking men (13 and 0%, respectively). The shared familial environmental (c(2)) influence for BPb was 37% for men but only 3% for women. The association between BCd and BPb could be attributed entirely to environmental factors of mutual importance for levels of the two metals. Thus, blood metal concentrations in women reflect not only exposure, as previously believed, but to a considerable extent hereditary factors possibly related to uptake and storage. Further steps should focus on identification of these genetic factors and evaluation of whether women are more susceptible to exposure to toxic metals than men.
LONDON LETTER.
Authors: None G. O. M.
Journal: JAMA (1884)

London, June, 1884. No doubt many who intend visiting the meeting of the Medical Congress to be held at Copenhagen in August, will avail themselves of the offer of the Ocean Steam Yachting Company to take passengers to the meeting in their steam yacht "Ceylon" for a fare of £30 each person, this to include living on board in port, table wine, and boat service. This arrangement sounds pleasant, and will obviate the discomfort of living in crowded hotels. Since the suspension of the Contagious Diseases Acts, the various female Lock Hospitals in the towns where the acts were previously enforced seem to have been practically empty, whilst the percentage of venereal diseases amongst the troops seems to be on the increase, in spite of the assertion of those opposed to the working of the Contagious Diseases acts. A deputation of gentlemen opposed to state interference with prostitution have waited
Eosinophil Viability-enhancing Activity in Sputum from Patients with Bronchial Asthma: Contributions of Interleukin-5 and Granulocyte/Macrophage Colony-stimulating Factor
Authors: Tetsuya Adachi, Shinji Motojima, Akira Hirata, Takeshi Fukuda, Sohei Makino
Journal: American Journal of Respiratory and Critical Care Medicine (1995)

To investigate the mechanisms of eosinophil activation in the airways of patients with asthma, we attempted to detect eosinophil-activating cytokines in sputum extracts obtained from asthmatic patients during acute attacks or in remission by eosinophil survival assay. Purified guinea pig eosinophils were cultured in the presence or absence of sputum extracts, and the eosinophil viability was measured on Day 4. Eosinophil viability in the presence of sputum extracts derived from patients during moderate or severe attacks was significantly higher than that for sputum obtained from patients in remission or during mild attacks or from those with other respiratory diseases, including bronchiectasis and diffuse panbronchiolitis (p < 0.05). The total symptom score during the week prior to sputum collection correlated with the eosinophil viability (rs = 0.79, p < 0.01). Eosinophil viability-enhancing activity (EVEA) in the sputum of asthmatic patients with moderate or severe attacks was neutralized by anti-IL-5 antibody and by anti-GM-CSF antibody by 19.9 ± 13.7% and 76.9 ± 8.2% (mean ± SEM, n = 7), respectively. EVEA was completely neutralized by a combination of anti-IL-5 and anti-GM-CSF antibodies. There was a significant correlation between the concentration of eosinophil cationic protein (ECP) in sputum extracts and the eosinophil viability (rs = 0.54, p < 0.05). These findings suggest that IL-5 and GM-CSF are present in the sputum during asthma attacks and that these cytokines are at least partially responsible for eosinophil activation in asthma.
AMA Diagnostic and Treatment Guidelines Concerning Child Abuse and Neglect
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Editorial: Reserpine and breast cancer: a perspective
Authors: H. Jick
Journal: JAMA (1975)

The possibility of a connection between reserpine and cancer of the female breast is currently the subject of much scientific debate and is also causing anxiety and concern among both physicians and patients. The origin of this debate and concern was the publication of three studies—conducted in the United States, Britain, and Finland—that pointed to a statistical association between reserpine use and breast cancer.<sup>1-3</sup> The first study was suggested by data from a general purpose survey designed to assess possible relationships of many commonly used drugs to a variety of illnesses. The data came from patients hospitalized in the Boston area. The other two studies, prompted by the Boston findings, were specifically designed to determine whether or not a relationship existed between reserpine-like drugs and breast cancer. The designs of these studies have been criticized, especially selections of the control series.<sup>4</sup>However, such criticisms seem unjustified in the
TRANSCUTANEAL VIRUS INFECTIONS
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association News
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacology
Authors: Henry M. Whelpley
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal